Free Trial

Ieq Capital LLC Grows Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Twist Bioscience logo with Medical background
Remove Ads

Ieq Capital LLC boosted its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 21.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 62,034 shares of the company's stock after acquiring an additional 10,800 shares during the period. Ieq Capital LLC owned about 0.10% of Twist Bioscience worth $2,883,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Massachusetts Financial Services Co. MA increased its stake in Twist Bioscience by 215.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company's stock valued at $1,324,000 after purchasing an additional 20,035 shares during the last quarter. Barclays PLC lifted its holdings in shares of Twist Bioscience by 214.8% in the 3rd quarter. Barclays PLC now owns 153,039 shares of the company's stock valued at $6,913,000 after purchasing an additional 104,420 shares during the last quarter. FMR LLC boosted its position in shares of Twist Bioscience by 6.0% in the 3rd quarter. FMR LLC now owns 218,561 shares of the company's stock valued at $9,875,000 after purchasing an additional 12,327 shares during the period. Avanza Fonder AB acquired a new position in Twist Bioscience during the fourth quarter worth approximately $1,059,000. Finally, BNP Paribas Financial Markets lifted its stake in Twist Bioscience by 128.1% in the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company's stock valued at $1,718,000 after buying an additional 21,357 shares during the last quarter.

Analysts Set New Price Targets

A number of brokerages have recently commented on TWST. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the company an "overweight" rating in a report on Monday, February 3rd. JPMorgan Chase & Co. lifted their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research note on Tuesday, February 4th. Wolfe Research initiated coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They set an "outperform" rating and a $60.00 target price for the company. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Finally, Robert W. Baird lifted their target price on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $54.40.

Remove Ads

Check Out Our Latest Stock Analysis on Twist Bioscience

Twist Bioscience Price Performance

NASDAQ TWST traded up $0.52 during mid-day trading on Wednesday, hitting $41.33. The stock had a trading volume of 711,402 shares, compared to its average volume of 878,495. The company has a 50 day simple moving average of $47.80 and a 200 day simple moving average of $45.70. The company has a market cap of $2.47 billion, a price-to-earnings ratio of -12.23 and a beta of 1.87. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business's revenue for the quarter was up 24.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.75) EPS. Equities analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CFO Adam Laponis sold 5,886 shares of the business's stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the transaction, the chief financial officer now owns 110,096 shares in the company, valued at $4,762,752.96. The trade was a 5.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Emily M. Leproust sold 2,216 shares of the stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $52.70, for a total value of $116,783.20. Following the completion of the sale, the chief executive officer now owns 674,718 shares of the company's stock, valued at approximately $35,557,638.60. This trade represents a 0.33 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 37,180 shares of company stock valued at $1,821,971 in the last ninety days. Corporate insiders own 3.01% of the company's stock.

About Twist Bioscience

(Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

See Also

Institutional Ownership by Quarter for Twist Bioscience (NASDAQ:TWST)

Should You Invest $1,000 in Twist Bioscience Right Now?

Before you consider Twist Bioscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.

While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads